ZEGA Investments LLC Has $1.50 Million Stock Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

ZEGA Investments LLC lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 36.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,031 shares of the medical equipment provider's stock after buying an additional 802 shares during the period. ZEGA Investments LLC's holdings in Intuitive Surgical were worth $1,501,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. AlphaCore Capital LLC lifted its position in Intuitive Surgical by 4.2% during the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after acquiring an additional 18 shares in the last quarter. Second Line Capital LLC raised its stake in shares of Intuitive Surgical by 3.4% during the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock valued at $302,000 after purchasing an additional 19 shares during the period. Colonial Trust Co SC lifted its position in shares of Intuitive Surgical by 8.8% during the fourth quarter. Colonial Trust Co SC now owns 246 shares of the medical equipment provider's stock worth $128,000 after purchasing an additional 20 shares in the last quarter. Crown Wealth Group LLC lifted its holdings in Intuitive Surgical by 4.8% in the 1st quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock worth $218,000 after buying an additional 20 shares in the last quarter. Finally, FSM Wealth Advisors LLC boosted its position in Intuitive Surgical by 3.8% in the 1st quarter. FSM Wealth Advisors LLC now owns 546 shares of the medical equipment provider's stock valued at $270,000 after buying an additional 20 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ISRG. BTIG Research lifted their target price on Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Piper Sandler restated an "overweight" rating and set a $595.00 price objective (up previously from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Truist Financial upped their target price on Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Wall Street Zen upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Erste Group Bank restated a "hold" rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Thirteen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded up $6.28 during midday trading on Friday, hitting $476.16. The company's stock had a trading volume of 2,023,902 shares, compared to its average volume of 1,973,062. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $616.00. The firm's fifty day moving average price is $504.42 and its 200-day moving average price is $521.58. The firm has a market cap of $170.69 billion, a P/E ratio of 66.41, a P/E/G ratio of 4.99 and a beta of 1.59.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The company had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.35 billion. During the same period in the previous year, the firm posted $1.78 earnings per share. Intuitive Surgical's quarterly revenue was up 21.4% compared to the same quarter last year. As a group, research analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, SVP Mark Brosius sold 216 shares of the stock in a transaction on Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the transaction, the senior vice president owned 907 shares of the company's stock, valued at approximately $510,740.77. This represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Myriam Curet sold 4,500 shares of Intuitive Surgical stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the sale, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. This represents a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,839 shares of company stock valued at $7,896,972 in the last quarter. Corporate insiders own 0.70% of the company's stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.